Related Experiment Videos
Therapy for Kaposi's sarcoma: recent advances and experimental approaches
1HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892-1906, USA. yarchoan@helix.nih.gov
Journal of Acquired Immune Deficiency Syndromes (1999)
|August 3, 1999
Summary
Recent advancements show effective Kaposi
Area of Science:
- Oncology and Virology
Background:
- Kaposi's sarcoma (KS) therapy has seen significant progress.
- Understanding KS pathogenesis has opened avenues for novel treatments.
Purpose of the Study:
- To review recent therapeutic advancements for Kaposi's sarcoma.
- To highlight emerging experimental agents and treatment strategies.
Main Methods:
- Review of clinical trial data and preclinical studies.
- Analysis of chemotherapy, antiangiogenesis, and other novel agents.
- Consideration of the impact of anti-HIV treatment and etiological discoveries.
Main Results:
- Liposomal anthracyclines and paclitaxel demonstrate high efficacy.
- Antiangiogenesis agents (TNP-470, thalidomide) show promising responses.
- Oral 9-cis retinoic acid and a human chorionic gonadotropin-derived protein exhibit anti-KS activity.
Conclusions:
- Multiple effective chemotherapeutic and experimental agents are available for Kaposi's sarcoma.
- Targeting angiogenesis, viral factors, and immune status offers new therapeutic avenues.